Contrasting results have been also shown regarding the influence of Peroxisome proliferator-activated receptor-alpha (PPARα) and Peroxisome proliferator-activated receptor-gamma (PPARγ) polymorphisms in NAFLD pathogenesis. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.